Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban safety after pulmonary valve replacement or Fontan surgery
IRCT20220516054868N2Phase 4Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rivaroxaban in Cardiovascular Malformation (CVM), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Safety and tolerability of rivaroxaban. Started Dec 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on IRCT20220516054868N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220516054868N2.